The Daily Biotech Pulse: Merck’s Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
Here's a roundup of top developments in the biotech space over the last 24 hours:
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers
Allarity Therapeutics (NASDAQ:ALLR) stock rose 25.3% to $2.84 during Monday's after-market session. The market value of their outstanding shares is at $22.9 million.
Earnings Scheduled For February 14, 2022
Companies Reporting Before The Bell
• Weber (NYSE:WEBR) is projected to report quarterly loss at $0.06 per share on revenue of $310.78 million.
Earnings Outlook For Applied Genetic Tech
Applied Genetic Tech (NASDAQ:AGTC) is set to give its latest quarterly earnings report on Monday, 2022-02-14. Here's what investors need to know before the announcement.
Analysts estimate that Applied Genetic Tech will likely report an Earnings Per Share (EPS) of $-0.38.
Top 10 Trending Penny Stocks for Friday, Feb. 4, 2022 (Sentiment via Swaggy Stocks)
SOC Telamed (TLMD)
Exela Technologies (XELA)
Senseonics (SENS)
Applied Genetic Technologies (AGTC)
Reed's (REED)
Citius Pharmaceuticals (CTXR)
OceanPal (OP)
Exicure (XCUR)
Veru (VERU)
Gran Tierra Energy
52 Biggest Movers From Friday
Gainers
Knightscope, Inc. (NASDAQ: KSCP) surged 175.6% to close at $3.40 on Friday. The company, on Thursday, priced its IPO at $10 per share.
Watching IMV, Applied Genetic Technologies; Traders Circulate TipRanks Report ‘These 2 Penny Stocks Could Surge Over 400%, Says Wells Fargo’
https://blog.tipranks.com/these-2-penny-stocks-could-surge-over-400-says-wells-fargo/
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Applied Genetic Tech Q1 EPS $(0.40) Misses $(0.35) Estimate
Applied Genetic Tech (NASDAQ:AGTC) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.35) by 14.29 percent. This is a 33.33 percent increase over losses of $(0.60) per share